Butterbur for Canine Oral Melanoma: What the 2026 Trial Actually Found

A small clinical trial published in February 2026 tested a butterbur shoot extract in dogs with oral melanoma, and it produced a real result worth knowing about. Dogs who received the extract lived longer than historical comparison cases.

The same paper reports something that has been getting dropped in coverage. The extract did not prolong progression-free survival. It did not slow the tumors down. Overall survival improved; the time before the disease progressed did not (Noguchi et al., 2026).

That distinction matters more than any other sentence on this page, because the popular version of this story says butterbur slows aggressive tumors, and the study says the opposite. If you are considering this for your dog, you deserve the version the researchers actually published.

There is a second thing worth knowing before you go looking. The product in that trial is not the butterbur supplement sold in stores, and ordinary butterbur products carry a documented risk of liver injury.

Key Points

The trial was a combined phase 1 and phase 2 study. Nine dogs took part in the phase 1 safety portion and sixteen dogs with stage 3 oral melanoma in the phase 2 portion (Noguchi et al., 2026).

Every dog in the study had radiation therapy or surgery first. The extract was given afterward, not instead (Noguchi et al., 2026).

Overall survival was significantly longer than in historical controls. Progression-free survival was not improved (Noguchi et al., 2026).

Historical controls are the weakest common comparison group in oncology research, and the authors present the finding as "may improve the outcome" rather than as established (Noguchi et al., 2026).

Every dog in the phase 1 portion had a grade 1 ALT elevation, meaning a mild rise in a liver enzyme, and diarrhea. No dose-limiting toxicities were seen (Noguchi et al., 2026).

Butterbur plants contain pyrrolizidine alkaloids, which can damage the liver and are potentially carcinogenic. Only products processed to remove them should ever be considered, and some products labeled PA-free have still been linked to liver injury (National Center for Complementary and Integrative Health, n.d.).

The extract in this study was developed by the research group from Japanese butterbur shoots and standardized for petasin derivatives. It is not a commercially available supplement.

What the Study Was

Researchers had previously shown that petasin derivatives from Japanese butterbur shoots had anti-proliferative activity against canine oral melanoma cells in the laboratory. This trial was the step that follows that kind of finding: taking the agent into live patients to see whether it is safe and whether the laboratory activity translates (Noguchi et al., 2026).

The phase 1 portion enrolled nine dogs and escalated the dose to establish a safe level. The phase 2 portion then gave that dose to sixteen dogs with stage 3 oral melanoma, and compared their progression-free survival and overall survival against historical controls (Noguchi et al., 2026).

Every enrolled dog had already received radiation therapy or surgery as local treatment before the extract was started (Noguchi et al., 2026). This was tested as something added to standard local therapy. Nothing in the study speaks to what butterbur would do on its own, and no one should read it that way.

What It Found, and What It Did Not

The headline result: butterbur shoot extract significantly extended overall survival, and did not prolong progression-free survival (Noguchi et al., 2026).

Those two things pulling in different directions is genuinely interesting and it is also a reason for caution. Progression-free survival measures how long before the cancer visibly advances. Overall survival measures how long the dog lives. When a treatment improves the second without improving the first, one explanation is that the drug is doing something the progression measurement does not capture. Another is that the survival difference reflects something about the two groups being compared rather than the drug.

Which brings us to the comparison group.

Why "Historical Controls" Is the Sentence to Slow Down On

The sixteen dogs receiving the extract were compared against historical controls, meaning records of dogs treated in the past rather than a group of dogs enrolled at the same time and randomly assigned (Noguchi et al., 2026).

Historical comparisons are common in small veterinary studies and they are useful for deciding whether something is worth pursuing. They are also the design most likely to produce a survival difference that does not hold up. Dogs enrolled in a trial today get closer monitoring, more frequent rechecks, and owners who are engaged enough to enroll them. Staging practices and supportive care change over time. Any of those can move a survival curve without a drug doing anything.

Sixteen dogs is also a small number. A survival difference in sixteen patients can be real, and it can also shift substantially when the next forty are studied.

The authors' own conclusion is measured: the extract is safe to administer and may improve the outcome of canine oral melanoma (Noguchi et al., 2026). "May improve" is the honest ceiling on this finding, and any article claiming more than that has gone beyond the paper.

The Mechanism, and What Tier of Evidence It Sits On

The proposed mechanism is that petasin derivatives interfere with mitochondrial respiratory function in cancer cells, cutting into the energy supply those cells need. The group's earlier work demonstrated anti-proliferative activity in canine oral melanoma cells in culture (Noguchi et al., 2026).

Laboratory activity is where every drug starts and where most of them stop. It is a reason to run a trial, not evidence of clinical benefit. Presenting a cell-culture mechanism as an explanation of how a treatment is helping a specific dog puts a lot of weight on a thin beam.

The Safety Section That Usually Gets Left Out

Two separate safety issues belong here, and they are not the same issue.

In the trial itself. Every dog in the phase 1 portion had a grade 1 ALT elevation and diarrhea. Grade 1 means mild, and no dose-limiting toxicities occurred, which is a reasonable safety result for an oncology agent (Noguchi et al., 2026). It is not the same as no side effects, and a liver enzyme rising in every dog tested is a finding a veterinarian would want to monitor rather than ignore.

In butterbur products generally. This is the part that could actually hurt a dog whose owner reads about this study and goes shopping.

Butterbur plants contain pyrrolizidine alkaloids. These compounds can damage the liver, lungs, and blood circulation, and may cause cancer. Only butterbur products processed to remove them and labeled or certified as PA-free should be considered, and some products marketed as PA-free have still been associated with liver damage, which suggests the processing is not always reliable (National Center for Complementary and Integrative Health, n.d.). Cases of clinically apparent liver injury have been reported with commercial butterbur preparations, suspected to be due to residual pyrrolizidine alkaloid contamination (National Institute of Diabetes and Digestive and Kidney Diseases, 2019). The American Academy of Neurology stopped recommending butterbur for migraine prevention in 2015 over liver toxicity concerns (National Center for Complementary and Integrative Health, n.d.).

A broader review of the genus covers the same territory: pyrrolizidine alkaloid content and toxicology are central issues in how butterbur preparations are assessed (Kulinowski et al., 2022).

Put those together and the picture is clear enough. Giving a dog with cancer an over-the-counter butterbur supplement, with uncertain alkaloid content, potentially alongside chemotherapy or an NSAID, is not the same thing as the study, and it carries a liver risk the study does not address.

Why You Cannot Simply Buy This

The agent tested was developed by the research group from Japanese butterbur shoots and standardized for petasin derivatives (Noguchi et al., 2026). Most butterbur supplements on the market are made from the root of a different species and standardized for different purposes, primarily migraine prevention in people.

Different plant part, different species, different standardization, different intended use, no veterinary formulation, no established dosing for dogs outside the trial. Buying a bottle labeled butterbur does not put you closer to what these sixteen dogs received.

If this research interests you, the useful action is to ask your oncologist whether any trial of this agent is enrolling, not to source a substitute.

Where This Sits Alongside Real Treatment

Canine oral melanoma is aggressive and the standard approach is local control, surgery or radiation, with additional therapy layered on depending on stage and margins. Every dog in this trial had that local therapy first (Noguchi et al., 2026).

An experimental agent that may add survival time on top of standard treatment is worth studying. It is not a substitute for the treatment it was added to, and no owner should delay surgery or radiation while pursuing an herbal option. Our article on what dog cancer recurrence actually depends on covers why margins and staging drive so much of the outcome in cancers like this one.

Bring this study to your oncologist. Print it if you like. A good oncology team will not be offended by the question and will tell you plainly what they think of the evidence.

When to Contact a Veterinarian

If your dog has been diagnosed with oral melanoma, or if you are giving any supplement to a dog with cancer, contact your veterinary team promptly for:

Yellowing of the gums or the whites of the eyes, which can indicate liver problems.

A drop in appetite, vomiting, or diarrhea that persists or is severe.

Increased drinking or urination, lethargy, or weakness you cannot explain.

Bleeding from the mouth, drooling that is bloody or foul-smelling, dropping food, or reluctance to eat because of oral pain.

A mass in the mouth that is growing, ulcerating, or bleeding, or a loose tooth in an area where a mass is present.

New facial swelling or asymmetry.

Any sudden change in how your dog is doing.

Call before starting any supplement, not after, particularly one with a known liver signal in a dog who may also be receiving chemotherapy or an NSAID.

Questions to Ask Your Veterinarian

What stage is my dog's oral melanoma, and what does that mean for the options?

What is the plan for local control, and what comes after it?

Is my dog a candidate for any clinical trial, including trials of this agent or others?

Are there treatments here I should be considering that we have not discussed?

I read about butterbur shoot extract for oral melanoma. What do you make of that study?

Are there supplements you specifically want my dog to avoid during treatment?

What liver values are you monitoring, and how often?

What signs should send me back to you between appointments?

Sources

Kulinowski, Ł., Luca, S. V., Minceva, M., & Skalicka-Woźniak, K. (2022). A review on the ethnobotany, phytochemistry, pharmacology and toxicology of butterbur species (Petasites L.). Journal of Ethnopharmacology, 293, Article 115263. https://doi.org/10.1016/j.jep.2022.115263

National Center for Complementary and Integrative Health. (n.d.). Headaches and complementary health approaches: What the science says. https://www.nccih.nih.gov/health/providers/digest/headaches-and-complementary-health-approaches-science

National Institute of Diabetes and Digestive and Kidney Diseases. (2019). Butterbur. In LiverTox: Clinical and research information on drug-induced liver injury. https://www.ncbi.nlm.nih.gov/books/NBK547997/

Noguchi, S., Furuya, M., Honda, K., Ito, R., & Akao, Y. (2026). Clinical impact of butterbur shoot extract in dogs with oral melanoma: A combined phase 1 and 2 clinical trial. BMC Veterinary Research, 22(1). https://doi.org/10.1186/s12917-026-05326-w